A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation

References

• Appell RA. (1997). Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology, 50:90–6; discussion 97.
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, Anderström C, Mattiasson A. (1998). Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol, 81:801–810.
   PubMedGoogle Scholar
• Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. (1998). Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol, 81:42–48.
   PubMedGoogle Scholar
• Kelleher CJ, Reese PR, Pleil AM. (2002). Health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care, 8:608–615.
   Google Scholar
• Pleil AM, Reese PR, Kelleher CJ, Okano GJ. (2001). Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Health Econ Prev Care, 2:69–75.
   Google Scholar
• Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. (1999). Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct, 10:283–289.
   PubMedGoogle Scholar
• Malone-Lee J, Shaffu B, Anand C, Powell C. (2001). Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol, 165:1452–1456.
   PubMed Web of Science ®Google Scholar
• Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS et al. (2002). Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol, 9:247–252.
   PubMed Web of Science ®Google Scholar
• Homma Y, Paick JS, Lee JG, Kawabe K; Japanese and Korean Tolterodine Study Group. (2003). Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int, 92:741–747.
   PubMed Web of Science ®Google Scholar
• Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. (2001). Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol, 19:141–147.
   PubMed Web of Science ®Google Scholar
• Olsson B, Szamosi J. (2001). Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet, 40:135–143.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group. (2001). Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology, 57:414–421.
   PubMed Web of Science ®Google Scholar
• Kreilgard B, Jacobsen LO, Hoeck U, Kristensen H, Gren T, Nilvebrant L, et al. (2004). Therapeutic formulation for administering tolterodine with controlled release. United States Patent: 6,770,295 B1; August 3.
   Google Scholar
• Patel HT, Shah AJ, Khandelwal SR, Patel HF, Patel MD. (2009). MR cholangiopancreatography at 3.0 T. Radiographics, 29:1689–1706.
   PubMed Web of Science ®Google Scholar
• Wang H. (2009). Controlled-release tolterodine compositions and methods. United States Patent: 2009/0192228 A1; July 30.
   Google Scholar
• Hiremath PS, Saha RN. (2008). Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations. Int J Pharm, 362:118–125.
   PubMed Web of Science ®Google Scholar
• Lamoudi L, Chaumeil JC, Daoud K. (2012). Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M. Drug Dev Ind Pharm, 38:515–520.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Ryu SG, Cui JH. (1999). Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm, 25:493–501.
   PubMed Web of Science ®Google Scholar
• Chaibva FA, Khamanga SM, Walker RB. (2010). Swelling, erosion and drug release characteristics of salbutamol sulfate from hydroxypropyl methylcellulose-based matrix tablets. Drug Dev Ind Pharm, 36:1497–1510.
   PubMed Web of Science ®Google Scholar
• Zugasti ME, Zornoza A, Goñi Mdel M, Isasi JR, Vélaz I, Martín C et al. (2009). Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets. Drug Dev Ind Pharm, 35:1264–1270.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Ryu SG, Cui JH. (1999). Controlled release of dual drug-loaded hydroxypropyl methylcellulose matrix tablet using drug-containing polymeric coatings. Int J Pharm, 188:71–80.
   PubMed Web of Science ®Google Scholar
• Sankalia JM, Sankalia MG, Mashru RC. (2008). Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC. J Control Release, 129:49–58.
   PubMed Web of Science ®Google Scholar
• Cao QR, Choi YW, Cui JH, Lee BJ. (2005). Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. J Control Release, 108:351–361.
   PubMed Web of Science ®Google Scholar
• Cao QR, Choi YW, Cui JH, Lee BJ. (2005). Effect of solvents on physical properties and release characteristics of monolithic hydroxypropylmethylcellulose matrix granules and tablets. Arch Pharm Res, 28:493–501.
   PubMed Web of Science ®Google Scholar
• Saxen V, Zaheer Z, Farooqui M. (2006). Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form. Ind J Chem Tech, 13:242–246.
   Google Scholar
• Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. (2006). Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm, 316:86–92.
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. (1987). A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release, 5:37–42.
   Google Scholar
• Escudero JJ, Ferrero C, Jiménez-Castellanos MR. (2008). Compaction properties, drug release kinetics and fronts movement studies from matrices combining mixtures of swellable and inert polymers: effect of HPMC of different viscosity grades. Int J Pharm, 351:61–73.
   PubMed Web of Science ®Google Scholar
• Sriamornsak P, Thirawong N, Korkerd K. (2007). Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm, 66:435–450.
   PubMed Web of Science ®Google Scholar
• Viridén A, Wittgren B, Andersson T, Larsson A. (2009). The effect of chemical heterogeneity of HPMC on polymer release from matrix tablets. Eur J Pharm Sci, 36:392–400.
   PubMed Web of Science ®Google Scholar
• Viridén A, Wittgren B, Larsson A. (2011). The consequence of the chemical composition of HPMC in matrix tablets on the release behaviour of model drug substances having different solubility. Eur J Pharm Biopharm, 77:99–110.
   PubMed Web of Science ®Google Scholar
• Ford JL, Rubinstein MH, Hoagen JE. (1985). Formulation of sustained release promethazine hydrochloride tablets using hydroxypropylmethylcellulose matrices. Int J Pharm, 24:327–338.
   Google Scholar
• Martini A, Montagno Cappuccinello M, Artico R, Muggetti L, De Ponti R. (1995). Hydrophilic matrices as controlled-release formulations for a 5a-reductase inhibitor. Pharm Pharmacol Cummun, 1:555–558.
   Google Scholar
• Kim H, Fassihi R. (1997). Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. J Pharm Sci, 86:323–328.
   PubMed Web of Science ®Google Scholar
• Viridén A, Larsson A, Schagerlöf H, Wittgren B. (2010). Model drug release from matrix tablets composed of HPMC with different substituent heterogeneity. Int J Pharm, 401:60–67.
   PubMedGoogle Scholar
• Costa P, Sousa Lobo JM. (2001). Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Dev Ind Pharm, 27:811–817.
   Google Scholar
• Hua TC, Pan A, Chan C, Poo YK, Skinner MH, Knadler MP, Gonzales CR, Wise SD. (2003). Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol, 57:652–656.
   Google Scholar